Dhansa Labs opened lower at ₹26.10, compared with its previous close of ₹27.45. During today's session, the stock has traded between ₹26.10 and ₹26.10, with an average traded price of ₹26.10. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 3 years ago in Dhansa Labs is now worth
₹ 2,924.00
resulting in a loss of
₹ 7,076.00 (70.76%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-1.35 (-4.92%)
Day High
₹26.10
Day Low
₹26.10
Day Open
₹26.10
Prev Close
₹27.45
Volume
6,000
Value Traded
₹0.02 Cr
1W Return
0.77%
1M Return
-26.99%
3M Return
13.48%
6M Return
11.30%
1Y Return
-38.59%
Market Cap (₹ Cr.)
70
PE Ratio
13.40
PB Ratio
0.92
Dividend Yield
-
ROE
5.59%
ROCE
8.48%
Book Value (₹)
29.87
Face Value (₹)
10.00
EPS (TTM)
0.28
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
0.77%
6 Week
-
1 Month
-26.99%
3 Month
13.48%
9 Month
-27.60%
Dhansa Labs updates website to dhansalabs.com
Dhansa Labs Limited has changed its corporate website address from https://ambeylab.com/ to https://dhansalabs.com/ with immediate effect. This update follows the company's recent name change from Ambey Laboratories Limited to Dhansa Labs Limited. The intimation was made to the National Stock Exchange of India under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2mo agoDhansa Labs revenue rises 10.82%, plans Rs 30 crore expansion
Dhansa Labs reported a 10.82% increase in revenue to ₹14,153.72 lakhs and a 15.47% rise in PAT to ₹552.26 lakhs for FY26. The company announced a ₹30 crore investment to expand Atrazine manufacturing capacity, targeting ₹120-140 crores in additional revenue. Additionally, subsidiaries are developing a ₹120 crore CBG project and a biomass pellet venture, with the CBG plant set to commence operations by July 2027.
4mo agoDhansa Labs FY26 PAT rises 15.47% to ₹552.26 lakh
Dhansa Labs Limited reported a 15.47% increase in Profit After Tax (PAT) to ₹552.26 lakh for FY26, with revenue from operations rising 7.82% to ₹14,153.72 lakh. EBITDA grew 6.31% to ₹1,221.80 lakh. The company allotted convertible equity warrants worth ₹4,999.99 lakh and is expanding capacity through Atrazine manufacturing and renewable energy projects via its subsidiaries.
4mo agoDhansa Labs' Subsidiary Acquires Land in Rajasthan for Biogas Pellet Project at ₹93,09,362
Dhansa Labs Limited's wholly owned subsidiary, Dhansa Biofuels Power Private Limited, has acquired approximately 14.32 Bigha of land in Village Roteda, District Bundi, Rajasthan, from Mrs. Rami Bai for a total cash consideration of Rs. 93,09,362. The land, identified at Khasra Nos. 506 and 519, is intended for the establishment of a Biogas Pellet Project as part of the subsidiary's expansion in the renewable energy sector. The transaction is not a related party transaction, requires no regulatory approvals, and is governed by an agreement dated 7th May, 2026. The disclosure was filed with the National Stock Exchange of India Ltd. on 8th May, 2026, under Regulation 30 of the SEBI Listing Regulations.
5mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹524.70 | +1.91% | ₹44,293.56 | 18.67 | -22.99% | |
| ₹2,130.00 | -0.07% | ₹32,315.96 | 27.65 | -40.25% | |
| ₹414.25 | -0.52% | ₹20,677.11 | 35.84 | -21.51% | |
| ₹3,592.40 | +1.51% | ₹16,145.00 | 21.74 | -28.25% | |
| ₹721.25 | -0.88% | ₹6,507.15 | 10.48 | -12.04% | |
| ₹200.05 | -0.03% | ₹3,890.35 | 31.33 | -33.88% | |
| ₹866.70 | +1.70% | ₹3,863.60 | 12.82 | -41.37% | |
| ₹128.12 | -2.99% | ₹3,001.13 | 249.15 | -35.34% | |
| ₹221.66 | +0.52% | ₹2,874.24 | 104.93 | -12.06% | |
| ₹476.65 | -0.44% | ₹2,217.32 | 22.60 | +33.80% | |
| ₹580.90 | +1.39% | ₹1,690.29 | 13.30 | -21.76% | |
| ₹989.30 | +1.93% | ₹1,644.32 | 11.27 | -59.39% |
An investment of ₹10,000 made 3 years ago in Dhansa Labs is now worth
₹ 2,924.00
resulting in a loss of
₹ 7,076.00 (70.76%)
Note: Past profits do not guarantee future returns.
